Global Pharmaceutical Excipients Market | Future and Technological Advancement 2025
Pharmaceutical excipients are crucial contents of a formulation that enable effective drug absorption. Excipients must suit the intended dosage form and comply with regulatory requirements i.e. pharmacopeial standards to ensure finished product quality. Moreover, their compatibility is crucial in dosage forms that involves taste masking, coating, controlled and sustained release, and oil base (emulsifiers). The International Pharmaceutical Excipient Councils (IPE) governs the global pharmaceutical excipient manufacturing by providing harmonized excipient guidelines to manufacturers.
To get holistic SAMPLE of the report, please click: https://www.coherentmarketinsights.com/insight/request-sample/124
Excipients used in drug manufacturing serve as binders, diluents, glidents, or disintegrants. Thus, multifunctional excipients can lower the drug development and manufacturing cost of the product. Generics market has witnessed robust growth in recent times, owing to patent expiries, in turn acting as a major factor driving demand for pharmaceutical excipients. Moreover, meeting growing demand for pharmaceutical products and large patient population base would propel growth of pharmaceutical excipients market. However, stringent regulations, especially inspection of manufacturing sites by the regulatory authorities such as the FDA, MHRA and TGA has impacted the supply of pharmaceutical excipients globally.
China and India are the major suppliers of pharmaceutical excipients outside the U.S. and European markets. China is the largest supplier of low cost API and excipients. Demand for high-quality and functional excipients is high in developed markets, while emerging economies tend to prefer low cost alternatives.
The global pharmaceutical excipients market was valued at US$ 5,394.2 million in 2015 and is expected to witness a robust CAGR of 6.9% during the forecast period (2016 – 2024).
Oral and topical dosage forms driving the pharmaceutical excipients market growth
Consumption of excipients is very high in production of oral dosage forms such as tablets, capsules and liquids, compared to parenteral. The growth of excipients usage in oral dosage forms is expected to be 7.2% during the forecast period. Local players entering the pharmaceutical industry mark their entry with oral dosage forms, which are easier to manufacture. India, Brazil, China and U.S. are few major pharmaceutical excipients markets in terms of presence of regional pharmaceutical players. Thus, demand for excipients is projected to be high in such economies. Moreover, with growing topical solutions (cream, gel, eye drops, skin patch) in dermatology, and pain management categories, demand for excipients is also expected to grow consequently.
Patent expiries to provide opportunities for pharmaceutical excipient manufacturers
Symbicort (Budesonide/Formoterol Fumarate Dihydrate), Cialis (Tadalafi), Velcade (Bortezomib), Alimta (Pemetrexed), Vytorin (Ezetimibe and Simvastatin), Cubicin (Daptomycin), Reyataz (Atazanavir) and Sandostatin LAR (Octreotide Acetate) are some of the major blockbuster brands going off-patent in 2017. This will pave way for generic brands boosting the demand for respective pharmaceutical excipients. According to the McKinsey’s Global Generics report, nearly US$ 97 billion of drugs will go off-patent during 2017 – 2019.
Ask for customization: https://www.coherentmarketinsights.com/insight/request-customization/124
In addition, advent of biosimilars would further propel growth of the pharmaceutical excipients market. Companies are investing in development of biosimilars to capitalize on this billion dollar market opportunity. However, strict regulatory hold over approval of biosimilars is slowing the approval of biosimilars being developed, in turn hampering growth of the pharmaceutical excipients market.
Growing demand for low cost medicines
Affordable healthcare is the primary objective of health regulators globally, something that is propagated by various such initiatives in place such as Obama Care Act and the actions of Drug Price Control Order (DPCO) in India. The DPCO has capped the prices of over 467 drugs to cater to unmet need of population with low income levels. According to the IMS Health 2015 data, average price of branded products has increased from US$ 71.91 in 2010 to US$ 91.92 in 2015. On the other hand, average price of generic products has declined from US$ 26.23 in 2010 to US$ 20.92 in 2015. Pricing pressure and high competition are major attributable factors to this decline. This has further contributed to wards the growth of pharmaceutical excipients market.
Increase in preferences for low cost medicine will drive the demand for pharmaceutical excipients, especially the on form natural sources to reduce production cost of the product.
You may be interested
Air Pollution Linked with Increasing Mortality RateMohit Joshi - September 19, 2018
Researchers establish link between air pollution and the increasing mortality rate in urban areas, according to a new study published in March 2018. A study found that…
Blood Collection Tubes Market Growth, Trend, Demand and Future Forecast 2018-26Albert R - September 19, 2018
Coherent Market Insights has announced the addition of the “Blood Collection Tubes Market Size Status and Forecast 2026”, The report classifies the global Blood Collection Tubes Market…
Pet Health Products Market: Know the Key Growth Drivers Developments and InnovationsAlbert R - September 19, 2018
Coherent Market Insights has announced the addition of the “Pet Health Products Market Size Status and Forecast 2026”, The report classifies the global Pet Health Products Market in a…